Anticancer activity and mechanisms of diacetyldianhydrogalactitol on hepatoma QGY-7703 cells:

Xue Yan Zhang,Xue Lian Yan,Wei Guo,Bo Xu,Li Min,Zhou Ying,Jing Rong Cui
DOI: https://doi.org/10.1097/CAD.0b013e328330c7b9
2009-01-01
Anti-Cancer Drugs
Abstract:Diacetyldianhydrogalactitol (DADAG) is a member of the hexitols which shows a significant anticancer effect. Despite the fact that the antitumor effects of DADAG have been studied in a number of cell lines, the mechanism of its action remains unclear. Herein, we explored antitumor effects of DADAG and the possible mechanisms by which it inhibited the growth of human hepatocellular carcinoma cell QGY-7703 and its derived xenograft tumors. Cell proliferation was evaluated with the sulforhodamine B assay in vitro. The results suggested that DADAG had mild anti proliferative activity on QGY-7703 cells. The antitumor effect of DADAG was assessed in nude mice xenografted with QGY-7703 cells. We found that DADAG significantly inhibited the tumor growth. Flow cytometry results indicated that the retarded cell proliferation is associated with increased G(2)/M cell cycle arrest. Further studies showed that the induced G(2)/M cell cycle arrest is, at least partially, attributed to an upregulation of cyclin B1, phospho-cell division cycle 2 (cdc2) (Thr(15)), phospho-cdc2 (Thr(161)), and cdc25c protein expression, and a decrease in cdc2 protein expression. Taken together, our data show that DADAG has mild proliferative effects on QGY-7703 cells in vitro, but it significantly inhibits the growth of QGY-7703 in a xenograft model in vivo. The modulation of several cell cycle progression regulation proteins responsible for G(2)/M phase transition may account for its antitumor effects. Anti-Cancer Drugs 20:926-931 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
What problem does this paper attempt to address?